2016 - Fellow of the Australian Academy of Health and Medical Science
Richard F. Kefford mainly focuses on Melanoma, Internal medicine, Oncology, Cancer research and Surgery. Richard F. Kefford has included themes like Cancer and Pathology in his Melanoma study. His research in Clinical trial, Pembrolizumab, Adverse effect, Clinical endpoint and Survival rate are components of Internal medicine.
Richard F. Kefford interconnects Phases of clinical research, V600E, Metastasis, Genotype and Stage in the investigation of issues within Oncology. His Cancer research research is multidisciplinary, relying on both Protein kinase A, Mutant, Molecular biology, Drug resistance and PTEN. His studies examine the connections between Surgery and genetics, as well as such issues in Gastroenterology, with regards to Randomized controlled trial and Rash.
Richard F. Kefford mainly investigates Melanoma, Internal medicine, Oncology, Cancer research and Dabrafenib. His primary area of study in Melanoma is in the field of Vemurafenib. His Internal medicine research includes elements of Gastroenterology and Surgery.
His work carried out in the field of Oncology brings together such families of science as Metastatic melanoma, Chemotherapy, Hazard ratio, Stage and Ipilimumab. His Cancer research research incorporates elements of Mutation, Cell cycle, Mutant and MAPK/ERK pathway. His Dabrafenib study combines topics from a wide range of disciplines, such as Phases of clinical research, Dermatology, Tolerability, Trametinib and Pharmacology.
Melanoma, Internal medicine, Oncology, Dabrafenib and Trametinib are his primary areas of study. His Melanoma study results in a more complete grasp of Cancer research. When carried out as part of a general Internal medicine research project, his work on Clinical trial, Pembrolizumab, Adjuvant and Survival rate is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
His studies in Oncology integrate themes in fields like Biomarker, Metastatic melanoma, V600E, Hazard ratio and Stage. His study in Dabrafenib is interdisciplinary in nature, drawing from both Mutant, Pharmacology and Phases of clinical research. Richard F. Kefford usually deals with Cancer and limits it to topics linked to Adverse effect and Vemurafenib.
His primary areas of study are Melanoma, Internal medicine, Oncology, Cancer and Clinical trial. To a larger extent, he studies Cancer research with the aim of understanding Melanoma. Richard F. Kefford has researched Internal medicine in several fields, including Gastroenterology and Surgery.
His Gastroenterology research integrates issues from Survival rate and Randomized controlled trial. MEK inhibitor is closely connected to Combination therapy in his research, which is encompassed under the umbrella topic of Surgery. In his study, Stage, Ipilimumab, Pseudoprogression and Progressive disease is strongly linked to Hazard ratio, which falls under the umbrella field of Oncology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi.
The New England Journal of Medicine (2013)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez.
The New England Journal of Medicine (2012)
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez.
The New England Journal of Medicine (2012)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi.
The Lancet (2014)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani;Kadir C. Akdemir;B. Arman Aksoy;Monique Albert.
Pan-cancer analysis of whole genomes
Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart.
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long;Alexander M. Menzies;Adnan M. Nagrial;Lauren E. Haydu.
Journal of Clinical Oncology (2011)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Gerald S Falchook;Georgina V Long;Georgina V Long;Razelle Kurzrock;Kevin B Kim.
The Lancet (2012)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long;A. Hauschild;M. Santinami;V. Atkinson.
The New England Journal of Medicine (2017)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long;Uwe Trefzer;Michael A. Davies;Richard F. Kefford.
Lancet Oncology (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: